Neuroscience Today—June 10, 2026

This week’s Neuroscience update highlights regulatory approvals, positive Phase IIb migraine and Parkinson’s data, and collaborations advancing brain disorder therapeutics.

In Today’s Newsletter

Dive deeper

💊 Roche and Nurix partner on bexobrutideg BTK degrader [1] [Global • 08 Jun 2026]

https://www.roche.com/media/releases/med-cor-2026-06-08
Context: Bexobrutideg (NX-5948) is Nurix’s investigational oral BTK degrader, planned for Phase 3 initiation in second-line CLL in summer 2026.
Key point: Roche and Nurix entered an exclusive licensing and collaboration agreement to co-develop and co-commercialise bexobrutideg across malignant haematology, immunology, and neurology.
Implication: Signals pipeline investment and modality expansion.

🧠 Lundbeck and Cradle use AI for CNS antibody discovery [2] [EU • 03 Jun 2026]

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-partners-with-cradle-to-discover-and-optimize-brain-disorder-treatments,c4357042
Context: The partnership initially targets two antibody programs for CNS diseases using Cradle’s AI-powered protein design platform.
Key point: Lundbeck will use an end-to-end AI-guided protein-engineering workflow to optimize biotherapeutic candidates.
Implication: Signals pipeline investment and modality expansion.

🧬 Lundbeck reports positive bocunebart Phase IIb migraine data [3] [US • 04 Jun 2026]

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-positive-phase-iib-data-for-bocunebart–lu-ag09222–anti-pacap-mab–in-migraine-pr,c4357979
Context: PROCEED evaluated bocunebart (Lu AG09222), an anti-PACAP monoclonal antibody, in migraine prevention after one to four prior preventive failures.
Key point: The IV part of PROCEED met its primary endpoint, reducing monthly migraine days versus placebo over Weeks 1–12.
Implication: May influence prescriber choice and payer reviews pending full data.

🧑‍⚕️ Teva shares AUSTEDO real-world HD chorea outcomes [4] [US • 05 Jun 2026]

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Presents-New-Data-on-AUSTEDO-deutetrabenazine-tablets-and-AUSTEDO-XR-deutetrabenazine-extended-release-tablets-that-Show-Patient–and-Caregiver-Reported-Improvements-in-Huntingtons-Disease-Chorea/default.aspx
Context: Teva presented decentralized, real-world survey data on Huntington’s disease chorea at the Advanced Therapeutics in Movement & Related Disorders Congress.
Key point: Patients and caregivers reported quality-of-life improvements after AUSTEDO or AUSTEDO XR treatment.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

⚡ AbbVie wins EU acute migraine approval for AQUIPTA [5] [EU • 02 Jun 2026]

https://news.abbvie.com/2026-06-02-AbbVie-Announces-European-Commission-Approval-of-AQUIPTA-R-atogepant-for-the-Acute-Treatment-of-Migraine-in-Adults
Context: AQUIPTA (atogepant) is an oral CGRP receptor antagonist already approved in the EU for migraine prophylaxis in eligible adults.
Key point: The European Commission approved AQUIPTA as an as-needed acute treatment for migraine in adults, with or without aura.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 IntraBio submits EMA variation for AQNEURSA in A-T [6] [EEA • 05 Jun 2026]

https://www.businesswire.com/news/home/20260605049248/en/IntraBio-Announces-Submission-of-Variation-Application-to-the-European-Medicines-Agency-for-AQNEURSA-for-Ataxia-Telangiectasia
Context: AQNEURSA (levacetylleucine) is approved in the EEA for neurological manifestations of Niemann-Pick disease type C in specified patients.
Key point: IntraBio submitted an EMA variation application to expand AQNEURSA’s label to Ataxia-Telangiectasia.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Neurogene completes NGN-401 dosing in Rett trial [7] [US • 08 Jun 2026]

https://www.businesswire.com/news/home/20260608913151/en/Neurogene-Announces-Successful-Completion-of-Dosing-in-Embolden-Registrational-Trial-of-NGN-401-for-Rett-Syndrome
Context: Embolden is a single-arm, open-label, baseline-controlled registrational trial of one-time NGN-401 gene therapy in females with Rett syndrome.
Key point: Neurogene completed dosing, enrolling 25 participants; topline Embolden data are expected in 2H 2027.
Implication: May influence prescriber choice and payer reviews pending full data.

📉 Bial’s ACTIVATE Phase 2b misses in GBA-PD [8] [Europe, North America • 09 Jun 2026]

https://www.businesswire.com/news/home/20260608846221/en/Bial-Reports-Topline-Results-From-ACTIVATE-Phase-2b-Study-in-GBAAssociated-Parkinsons
Context: ACTIVATE enrolled genetically confirmed GBA-associated Parkinson’s patients across Europe and North America.
Key point: BIA 28-6156 (pariceract) did not meet its primary or key secondary efficacy endpoints and Bial discontinued development in this indication.
Implication: May redirect development priorities and inform future Parkinson’s trial design.

Why it matters

Migraine remains active across both regulatory and clinical fronts, with AbbVie’s AQUIPTA approval and Lundbeck’s bocunebart data.
CNS drug discovery is leaning further into AI, biologics, and pathway differentiation.
Rare neurology programs continue to advance through regulatory submissions and registrational milestones.
Failed GBA-PD data from Bial underline the difficulty of disease-modifying Parkinson’s development.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page

🎯 Catch up on the Top Neuroscience news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is bexobrutideg (NX-5948), and who is developing it?

Bexobrutideg is Nurix’s investigational oral BTK degrader. Roche and Nurix will co-develop and co-commercialise it across malignant haematology, immunology, and neurology [1].

What did Lundbeck report for bocunebart in migraine prevention?

Lundbeck said the IV part of the Phase IIb PROCEED trial met its primary endpoint versus placebo over Weeks 1–12. Bocunebart targets PACAP, a pathway distinct from CGRP [3].

What changed for AbbVie’s AQUIPTA in Europe?

The European Commission approved AQUIPTA (atogepant) as an as-needed acute treatment for migraine in adults, with or without aura. It was already approved in the EU for migraine prophylaxis in eligible adults [5].

What did Teva’s AUSTEDO data show?

Teva presented real-world survey data suggesting patient- and caregiver-reported quality-of-life improvements after AUSTEDO or AUSTEDO XR treatment for Huntington’s disease chorea. The evidence is observational and survey-based [4].

What is the status of Neurogene’s NGN-401 Rett program?

Neurogene completed dosing in the Embolden registrational trial of NGN-401, a one-time investigational gene therapy for Rett syndrome. Topline data are expected in 2H 2027 [7].

What happened to Bial’s BIA 28-6156 in GBA-associated Parkinson’s?

The Phase 2b ACTIVATE study did not meet its primary or key secondary efficacy endpoints. Bial said it discontinued development of BIA 28-6156 for this indication [8].

Entities / Keywords

Roche, Nurix Therapeutics, bexobrutideg, NX-5948, BTK degrader, CLL, B-cell malignancies
Lundbeck, Cradle, AI protein engineering, CNS antibodies, brain disorders
Lundbeck, bocunebart, Lu AG09222, anti-PACAP mAb, PROCEED, migraine prevention
Teva, AUSTEDO, AUSTEDO XR, deutetrabenazine, Huntington’s disease chorea, myHDstory
AbbVie, AQUIPTA, atogepant, CGRP receptor antagonist, acute migraine, ECLIPSE
IntraBio, AQNEURSA, levacetylleucine, Ataxia-Telangiectasia, EMA, Niemann-Pick disease type C
Neurogene, NGN-401, Embolden, Rett syndrome, gene therapy, BLA
Bial, BIA 28-6156, pariceract, ACTIVATE, GBA-associated Parkinson’s, GBA1, GCase